United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

24 Feb 2017
Change (% chg)

€-0.85 (-0.81%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BAYGn.DE


Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic... (more)


Beta: 0.96
Market Cap(Mil.): €86,209.31
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.59


  BAYGn.DE Industry Sector
P/E (TTM): 20.27 28.84 29.63
EPS (TTM): 5.14 -- --
ROI: 7.73 13.44 12.96
ROE: 15.62 14.34 14.11

BRIEF-Bayer confident it will receive CFIUS approval for Monsanto takeover

* Ceo says assume that we will receive cfius approval for monsanto takeover Further company coverage: (Frankfurt newsroom)

Feb 22 2017

Bayer sees pesticides profits stagnating before Monsanto takeover

LEVERKUSEN, Germany German drugs and pesticides maker Bayer forecast a year without earnings growth for its agricultural products business on Wednesday, as it seeks to complete its $66 billion deal to take over U.S. seeds giant Monsanto .

Feb 22 2017

UPDATE 2-Bayer sees pesticides profits stagnating before Monsanto takeover

* Aims for mid 1-digit pct gain in 2017 adj group EBITDA (Adds quote from divisional head, shares, update on EU antitrust scrutiny)

Feb 22 2017

BRIEF-Bayer eyes more robust growth in agriculture towards yr-end

* Head of Crop Science unit Liam Conaon says agriculture markets likely to see more robust growth towards the end of 2017 and in 2018

Feb 22 2017

Covestro parent Bayer non-committal on any sale to industry peer

FRANKFURT, Feb 22 Bayer said that various ways to divest its 64 percent stake in plastics subsidiary Covestro were on the cards, when asked to comment on the possibility of a sale to an industry peer versus placing shares on the open stock market.

Feb 22 2017

Bayer predicts mid-single digit EBITDA rise in 2017

FRANKFURT, Feb 22 Bayer, the German drugmaker that is buying U.S. seed maker Monsanto, said it expected a mid-single digit percentage increase in adjusted core earnings for 2017, helped by fast growing revenues from stroke prevention pill Xarelto.

Feb 22 2017

Bayer to pay out 2.70 eur/shr dividend, in line with market view

FRANKFURT, Feb 21 Germany's largest drugmaker Bayer said on Tuesday it would propose an annual dividend of 2.70 euros per share to investors, in line with analysts' expectations and up from 2.50 euros a year earlier.

Feb 21 2017

BRIEF-Ionis earns $75 mln from Bayer for advancing IONIS-FXI Rx and IONIS-FXI-L Rx

* Ionis earns $75 million from Bayer for advancing IONIS-FXI Rx and IONIS-FXI-L Rx

Feb 14 2017

Regeneron pins hope on eczema drug as Eylea sales slow

Regeneron Pharmaceuticals Inc Chief Executive Leonard Schleifer signaled that the U.S. biotech was on track to reduce its reliance on its flagship drug Eylea, as the company awaits the approval of two potential blockbuster treatments.

Feb 09 2017

UPDATE 3-Regeneron pins hope on eczema drug as Eylea sales slow

* Shares rise as much as 4 pct (Adds conference call details; updates shares)

Feb 09 2017

More From Around the Web

Earnings vs. Estimates